ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.
Unternehmens-codeNDRA
Name des UnternehmensENDRA Life Sciences Inc
IPO-datumJun 28, 2017
Gegründet am2007
CEOMr. Alexander Y. Tokman
Anzahl der mitarbeiter21
WertpapierartOrdinary Share
GeschäftsjahresendeJun 28
Addresse3600 Green Ct Ste 350
StadtANN ARBOR
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl48105-2440
Telefon17343350468
Websitehttps://www.endrainc.com/
Unternehmens-codeNDRA
IPO-datumJun 28, 2017
Gegründet am2007
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten